Date: Tuesday 14th March 2023 Time: 14:00-14:45 GMT | 15:00-15:45 CET Speaker: Els Pattyn (Sanofi)
Who is this event intended for? Any statisticians working in the Pharmaceutical industry. What is the benefit of attending? Attendees will have the opportunity to see an example of JMP development for regulatory compliant calculation of immunogenicity cut-point.
Registration
Registration for this webinar is free to both Members of PSI and Non-Members.
Please click here to register.
Overview
"Immunogenicity represents a significant hurdle for the development of all biotherapeutics and biosimilars as it can affect both efficacy and safety of the treatment. Over the last decade industry and regulators succeeded in standardizing a tiered screening/confirmatory/titer testing approach for anti-drug antibodies (ADAs). Unlike assays to determine the concentration of biopharmaceuticals, ADA assays are semi-quantitative in nature, and therefore requiring error prone and complex statistical approaches for positivity cut-points at each tier of the testing paradigm.
To get around these hurdles, a solution has been created within Sanofi by the development of a fully-automated and validated script using the JMP statistical software. This script follows a pre-determined decision tree based on the latest recommendations from industry guidance, white papers and scientific best-practice. It is designed for both binding and neutralizing antibody methods used to support non-clinical and clinical studies in regulated environments (GLP/GcLP). The user-friendly interface allows application by any bioanalytical scientist without requiring deep statistical knowledge.
The script allows end-users to easily select the appropriate decision trees applicable for the specific needs of a given type of assay or study. The application accepts Excel files to upload assay response data and then makes outcome-dependent decisions based on best-practices for the chosen method and context. For example, the script will select the most appropriate normalization/transformation, apply adapted effects included in the mixed-effects model based on the study-design, optionally calculate analyst-specific cut-points in case of significant analyst-specific differences and adapt down-stream analysis in cases where no second-tier confirmatory data is available.
The validated version of this purpose-built statistical tool, named ImmunoStat Simple, allows immunogenicity cut-points to be calculated quickly and efficiently in a standardized way across multiple sites in a global organization, and the automated reporting is suitable for regulatory submissions. The successful implementation of this automated JMP script demonstrates how digital tools and automation can improve the efficiency and capabilities of modern bioanalytical laboratories."
Speaker details
Speaker
Biography
Els Pattyn
Els Pattyn is educated as a bio-engineer. After obtaining her PhD, she additional worked 8 years as a post-doctoral researcher at the University of Ghent in the immunology research, whereafter she took the role of scientist NANOBODY® characterization at Ablynx. After obtaining a master in statistical data analysis, she switched to Ablynx’ statistics team. By the acquisition of Ablynx by Sanofi in 2018, Els joined Sanofi’s Non Clinical Efficacy and Safety Statistics team, where she provides statistical support for mainly projects in immunology research, with focus on dose response modelling, design of experiments and immunogenicity assessment.
Scientific Meetings
PSI Pre-Clinical SIG Webinar: End-user Tool for Immunogenicity Cut-points Calculation
Date: Tuesday 14th March 2023 Time: 14:00-14:45 GMT | 15:00-15:45 CET Speaker: Els Pattyn (Sanofi)
Who is this event intended for? Any statisticians working in the Pharmaceutical industry. What is the benefit of attending? Attendees will have the opportunity to see an example of JMP development for regulatory compliant calculation of immunogenicity cut-point.
Registration
Registration for this webinar is free to both Members of PSI and Non-Members.
Please click here to register.
Overview
"Immunogenicity represents a significant hurdle for the development of all biotherapeutics and biosimilars as it can affect both efficacy and safety of the treatment. Over the last decade industry and regulators succeeded in standardizing a tiered screening/confirmatory/titer testing approach for anti-drug antibodies (ADAs). Unlike assays to determine the concentration of biopharmaceuticals, ADA assays are semi-quantitative in nature, and therefore requiring error prone and complex statistical approaches for positivity cut-points at each tier of the testing paradigm.
To get around these hurdles, a solution has been created within Sanofi by the development of a fully-automated and validated script using the JMP statistical software. This script follows a pre-determined decision tree based on the latest recommendations from industry guidance, white papers and scientific best-practice. It is designed for both binding and neutralizing antibody methods used to support non-clinical and clinical studies in regulated environments (GLP/GcLP). The user-friendly interface allows application by any bioanalytical scientist without requiring deep statistical knowledge.
The script allows end-users to easily select the appropriate decision trees applicable for the specific needs of a given type of assay or study. The application accepts Excel files to upload assay response data and then makes outcome-dependent decisions based on best-practices for the chosen method and context. For example, the script will select the most appropriate normalization/transformation, apply adapted effects included in the mixed-effects model based on the study-design, optionally calculate analyst-specific cut-points in case of significant analyst-specific differences and adapt down-stream analysis in cases where no second-tier confirmatory data is available.
The validated version of this purpose-built statistical tool, named ImmunoStat Simple, allows immunogenicity cut-points to be calculated quickly and efficiently in a standardized way across multiple sites in a global organization, and the automated reporting is suitable for regulatory submissions. The successful implementation of this automated JMP script demonstrates how digital tools and automation can improve the efficiency and capabilities of modern bioanalytical laboratories."
Speaker details
Speaker
Biography
Els Pattyn
Els Pattyn is educated as a bio-engineer. After obtaining her PhD, she additional worked 8 years as a post-doctoral researcher at the University of Ghent in the immunology research, whereafter she took the role of scientist NANOBODY® characterization at Ablynx. After obtaining a master in statistical data analysis, she switched to Ablynx’ statistics team. By the acquisition of Ablynx by Sanofi in 2018, Els joined Sanofi’s Non Clinical Efficacy and Safety Statistics team, where she provides statistical support for mainly projects in immunology research, with focus on dose response modelling, design of experiments and immunogenicity assessment.
Training Courses
PSI Pre-Clinical SIG Webinar: End-user Tool for Immunogenicity Cut-points Calculation
Date: Tuesday 14th March 2023 Time: 14:00-14:45 GMT | 15:00-15:45 CET Speaker: Els Pattyn (Sanofi)
Who is this event intended for? Any statisticians working in the Pharmaceutical industry. What is the benefit of attending? Attendees will have the opportunity to see an example of JMP development for regulatory compliant calculation of immunogenicity cut-point.
Registration
Registration for this webinar is free to both Members of PSI and Non-Members.
Please click here to register.
Overview
"Immunogenicity represents a significant hurdle for the development of all biotherapeutics and biosimilars as it can affect both efficacy and safety of the treatment. Over the last decade industry and regulators succeeded in standardizing a tiered screening/confirmatory/titer testing approach for anti-drug antibodies (ADAs). Unlike assays to determine the concentration of biopharmaceuticals, ADA assays are semi-quantitative in nature, and therefore requiring error prone and complex statistical approaches for positivity cut-points at each tier of the testing paradigm.
To get around these hurdles, a solution has been created within Sanofi by the development of a fully-automated and validated script using the JMP statistical software. This script follows a pre-determined decision tree based on the latest recommendations from industry guidance, white papers and scientific best-practice. It is designed for both binding and neutralizing antibody methods used to support non-clinical and clinical studies in regulated environments (GLP/GcLP). The user-friendly interface allows application by any bioanalytical scientist without requiring deep statistical knowledge.
The script allows end-users to easily select the appropriate decision trees applicable for the specific needs of a given type of assay or study. The application accepts Excel files to upload assay response data and then makes outcome-dependent decisions based on best-practices for the chosen method and context. For example, the script will select the most appropriate normalization/transformation, apply adapted effects included in the mixed-effects model based on the study-design, optionally calculate analyst-specific cut-points in case of significant analyst-specific differences and adapt down-stream analysis in cases where no second-tier confirmatory data is available.
The validated version of this purpose-built statistical tool, named ImmunoStat Simple, allows immunogenicity cut-points to be calculated quickly and efficiently in a standardized way across multiple sites in a global organization, and the automated reporting is suitable for regulatory submissions. The successful implementation of this automated JMP script demonstrates how digital tools and automation can improve the efficiency and capabilities of modern bioanalytical laboratories."
Speaker details
Speaker
Biography
Els Pattyn
Els Pattyn is educated as a bio-engineer. After obtaining her PhD, she additional worked 8 years as a post-doctoral researcher at the University of Ghent in the immunology research, whereafter she took the role of scientist NANOBODY® characterization at Ablynx. After obtaining a master in statistical data analysis, she switched to Ablynx’ statistics team. By the acquisition of Ablynx by Sanofi in 2018, Els joined Sanofi’s Non Clinical Efficacy and Safety Statistics team, where she provides statistical support for mainly projects in immunology research, with focus on dose response modelling, design of experiments and immunogenicity assessment.
Journal Club
PSI Pre-Clinical SIG Webinar: End-user Tool for Immunogenicity Cut-points Calculation
Date: Tuesday 14th March 2023 Time: 14:00-14:45 GMT | 15:00-15:45 CET Speaker: Els Pattyn (Sanofi)
Who is this event intended for? Any statisticians working in the Pharmaceutical industry. What is the benefit of attending? Attendees will have the opportunity to see an example of JMP development for regulatory compliant calculation of immunogenicity cut-point.
Registration
Registration for this webinar is free to both Members of PSI and Non-Members.
Please click here to register.
Overview
"Immunogenicity represents a significant hurdle for the development of all biotherapeutics and biosimilars as it can affect both efficacy and safety of the treatment. Over the last decade industry and regulators succeeded in standardizing a tiered screening/confirmatory/titer testing approach for anti-drug antibodies (ADAs). Unlike assays to determine the concentration of biopharmaceuticals, ADA assays are semi-quantitative in nature, and therefore requiring error prone and complex statistical approaches for positivity cut-points at each tier of the testing paradigm.
To get around these hurdles, a solution has been created within Sanofi by the development of a fully-automated and validated script using the JMP statistical software. This script follows a pre-determined decision tree based on the latest recommendations from industry guidance, white papers and scientific best-practice. It is designed for both binding and neutralizing antibody methods used to support non-clinical and clinical studies in regulated environments (GLP/GcLP). The user-friendly interface allows application by any bioanalytical scientist without requiring deep statistical knowledge.
The script allows end-users to easily select the appropriate decision trees applicable for the specific needs of a given type of assay or study. The application accepts Excel files to upload assay response data and then makes outcome-dependent decisions based on best-practices for the chosen method and context. For example, the script will select the most appropriate normalization/transformation, apply adapted effects included in the mixed-effects model based on the study-design, optionally calculate analyst-specific cut-points in case of significant analyst-specific differences and adapt down-stream analysis in cases where no second-tier confirmatory data is available.
The validated version of this purpose-built statistical tool, named ImmunoStat Simple, allows immunogenicity cut-points to be calculated quickly and efficiently in a standardized way across multiple sites in a global organization, and the automated reporting is suitable for regulatory submissions. The successful implementation of this automated JMP script demonstrates how digital tools and automation can improve the efficiency and capabilities of modern bioanalytical laboratories."
Speaker details
Speaker
Biography
Els Pattyn
Els Pattyn is educated as a bio-engineer. After obtaining her PhD, she additional worked 8 years as a post-doctoral researcher at the University of Ghent in the immunology research, whereafter she took the role of scientist NANOBODY® characterization at Ablynx. After obtaining a master in statistical data analysis, she switched to Ablynx’ statistics team. By the acquisition of Ablynx by Sanofi in 2018, Els joined Sanofi’s Non Clinical Efficacy and Safety Statistics team, where she provides statistical support for mainly projects in immunology research, with focus on dose response modelling, design of experiments and immunogenicity assessment.
Webinars
PSI Pre-Clinical SIG Webinar: End-user Tool for Immunogenicity Cut-points Calculation
Date: Tuesday 14th March 2023 Time: 14:00-14:45 GMT | 15:00-15:45 CET Speaker: Els Pattyn (Sanofi)
Who is this event intended for? Any statisticians working in the Pharmaceutical industry. What is the benefit of attending? Attendees will have the opportunity to see an example of JMP development for regulatory compliant calculation of immunogenicity cut-point.
Registration
Registration for this webinar is free to both Members of PSI and Non-Members.
Please click here to register.
Overview
"Immunogenicity represents a significant hurdle for the development of all biotherapeutics and biosimilars as it can affect both efficacy and safety of the treatment. Over the last decade industry and regulators succeeded in standardizing a tiered screening/confirmatory/titer testing approach for anti-drug antibodies (ADAs). Unlike assays to determine the concentration of biopharmaceuticals, ADA assays are semi-quantitative in nature, and therefore requiring error prone and complex statistical approaches for positivity cut-points at each tier of the testing paradigm.
To get around these hurdles, a solution has been created within Sanofi by the development of a fully-automated and validated script using the JMP statistical software. This script follows a pre-determined decision tree based on the latest recommendations from industry guidance, white papers and scientific best-practice. It is designed for both binding and neutralizing antibody methods used to support non-clinical and clinical studies in regulated environments (GLP/GcLP). The user-friendly interface allows application by any bioanalytical scientist without requiring deep statistical knowledge.
The script allows end-users to easily select the appropriate decision trees applicable for the specific needs of a given type of assay or study. The application accepts Excel files to upload assay response data and then makes outcome-dependent decisions based on best-practices for the chosen method and context. For example, the script will select the most appropriate normalization/transformation, apply adapted effects included in the mixed-effects model based on the study-design, optionally calculate analyst-specific cut-points in case of significant analyst-specific differences and adapt down-stream analysis in cases where no second-tier confirmatory data is available.
The validated version of this purpose-built statistical tool, named ImmunoStat Simple, allows immunogenicity cut-points to be calculated quickly and efficiently in a standardized way across multiple sites in a global organization, and the automated reporting is suitable for regulatory submissions. The successful implementation of this automated JMP script demonstrates how digital tools and automation can improve the efficiency and capabilities of modern bioanalytical laboratories."
Speaker details
Speaker
Biography
Els Pattyn
Els Pattyn is educated as a bio-engineer. After obtaining her PhD, she additional worked 8 years as a post-doctoral researcher at the University of Ghent in the immunology research, whereafter she took the role of scientist NANOBODY® characterization at Ablynx. After obtaining a master in statistical data analysis, she switched to Ablynx’ statistics team. By the acquisition of Ablynx by Sanofi in 2018, Els joined Sanofi’s Non Clinical Efficacy and Safety Statistics team, where she provides statistical support for mainly projects in immunology research, with focus on dose response modelling, design of experiments and immunogenicity assessment.
Careers Meetings
PSI Pre-Clinical SIG Webinar: End-user Tool for Immunogenicity Cut-points Calculation
Date: Tuesday 14th March 2023 Time: 14:00-14:45 GMT | 15:00-15:45 CET Speaker: Els Pattyn (Sanofi)
Who is this event intended for? Any statisticians working in the Pharmaceutical industry. What is the benefit of attending? Attendees will have the opportunity to see an example of JMP development for regulatory compliant calculation of immunogenicity cut-point.
Registration
Registration for this webinar is free to both Members of PSI and Non-Members.
Please click here to register.
Overview
"Immunogenicity represents a significant hurdle for the development of all biotherapeutics and biosimilars as it can affect both efficacy and safety of the treatment. Over the last decade industry and regulators succeeded in standardizing a tiered screening/confirmatory/titer testing approach for anti-drug antibodies (ADAs). Unlike assays to determine the concentration of biopharmaceuticals, ADA assays are semi-quantitative in nature, and therefore requiring error prone and complex statistical approaches for positivity cut-points at each tier of the testing paradigm.
To get around these hurdles, a solution has been created within Sanofi by the development of a fully-automated and validated script using the JMP statistical software. This script follows a pre-determined decision tree based on the latest recommendations from industry guidance, white papers and scientific best-practice. It is designed for both binding and neutralizing antibody methods used to support non-clinical and clinical studies in regulated environments (GLP/GcLP). The user-friendly interface allows application by any bioanalytical scientist without requiring deep statistical knowledge.
The script allows end-users to easily select the appropriate decision trees applicable for the specific needs of a given type of assay or study. The application accepts Excel files to upload assay response data and then makes outcome-dependent decisions based on best-practices for the chosen method and context. For example, the script will select the most appropriate normalization/transformation, apply adapted effects included in the mixed-effects model based on the study-design, optionally calculate analyst-specific cut-points in case of significant analyst-specific differences and adapt down-stream analysis in cases where no second-tier confirmatory data is available.
The validated version of this purpose-built statistical tool, named ImmunoStat Simple, allows immunogenicity cut-points to be calculated quickly and efficiently in a standardized way across multiple sites in a global organization, and the automated reporting is suitable for regulatory submissions. The successful implementation of this automated JMP script demonstrates how digital tools and automation can improve the efficiency and capabilities of modern bioanalytical laboratories."
Speaker details
Speaker
Biography
Els Pattyn
Els Pattyn is educated as a bio-engineer. After obtaining her PhD, she additional worked 8 years as a post-doctoral researcher at the University of Ghent in the immunology research, whereafter she took the role of scientist NANOBODY® characterization at Ablynx. After obtaining a master in statistical data analysis, she switched to Ablynx’ statistics team. By the acquisition of Ablynx by Sanofi in 2018, Els joined Sanofi’s Non Clinical Efficacy and Safety Statistics team, where she provides statistical support for mainly projects in immunology research, with focus on dose response modelling, design of experiments and immunogenicity assessment.
Upcoming Events
PSI Mentoring 2025
Date: Ongoing 6 month cycle beginning late April/early May 2024
Are you a member of PSI looking to further your career or help develop others - why not sign up to the PSI Mentoring scheme? You can expand your network, improve your leadership skills and learn from more senior colleagues in the industry.
PSI Introduction to Industry Training (ITIT) Course - 2025/2026
An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.
Joint PSI/EFSPI Visualisation SIG 'Wonderful Wednesday' Webinars
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
This is an interactive online training workshop providing an in-depth review of the estimand framework as laid out by ICH E9(R1) addendum with inputs from estimand experts, case studies, quizzes and opportunity for discussions. You will develop an estimand in a therapeutic area of interest to your company. In an online break-out room, you will join a series of team discussions to implement the estimand framework in a case study, aligning estimands, design, conduct, analysis, (assumptions + sensitivity analyses) to the clinical objective and therapeutic setting.
Maths Meets Medicine: Exploring Careers in the Pharmaceutical Industry
This session will showcase how careers in pharmaceutical statistics can be both rewarding and impactful, with a focus on how mathematics is integral to the development of medicines. Students will hear from industry experts, explore diverse career paths, and learn why continuing to study math is key to unlocking exciting opportunities in the healthcare sector.
Dissolution Testing: Time for Statistical (r)Evolution
Webinar dedicated to the topic of dissolution of oral solid dosage forms; opportunity to hear from statisticians working in the CMC field, with open question and answers.
In addition, the CMC Statistical Network Europe special interest group will discuss advocacy opportunities, have your say to contribute to the future direction.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
The BioMarin internship programme will enable students to gain valuable experience and knowledge of the processes and systems within BioMarin, whilst gaining an insight into the pharmaceutical/biotech industry.